How to Effectively Communicate Safety Risk to Your Patients With MS is organized by Medscape, LLC.

CME / ABIM MOC / CE Released: 1/7/2021
Valid for credit through: 1/7/2022

Accreditation:
For Physicians
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Goal Statement:
The goal of this activity is to provide learners with patient/physician vignettes that model appropriate communication with patients regarding safety risks associated with the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS).

Upon completion of this activity, participants will:
• Have increased knowledge regarding
○ Communication with patients regarding adverse events associated with DMTs for the management of MS
○ Patient characteristics that are associated with poorer disease outcomes